SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after discontinuing its compounded weight-loss pill amid escalating federal regulatory pressure, leading to a polarized community debate over whether this represents a critical misstep or a calculated strategic maneuver to remove uncertainty and gain publicity.

OpenAI pioneers large-language models like GPT and DALL·E, enabling advanced AI applications. Their research emphasizes both cutting-edge capability and responsible deployment strategies.

OpenAI PreStocks

The symbol $OPENAI CRYPTO, presented as "OpenAI PreStocks," is trending amidst widespread community discussion labeling it a scam and questioning its legitimacy due to its clear lack of affiliation with the actual OpenAI company.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending as community discussion intensifies around its status as an undervalued "safety" stock with a high dividend yield and anticipated strong earnings, even as a significant debate rages over Berkshire Hathaway's recent filing to potentially sell its large stake.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo Finance is trending due to its rapid expansion in real-world asset tokenization, including launching over 200 tokenized assets on Solana and receiving EU regulatory approval, further bolstered by the SEC's decision to close its investigation without charges. The community is split between bullish sentiment for its institutional partnerships and RWA leadership, and concerns over the potential impact of upcoming large token unlocks.

AMN Healthcare Services, Inc. engages in the provision of healthcare workforce solutions and staffing services to healthcare facilities across the nation. Its workforce solutions include managed services programs and recruitment process outsourcing. It operates through the following segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment includes travel nurse staffing, rapid response nurse staffing and labor disruption, allied staffing, local staffing, and revenue cycle solutions businesses. The Physician and Leadership Solutions segment offers locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement businesses. The Technology and Workforce Solutions segment focuses on language interpretation, vendor management systems, workforce optimization, recruitment process outsourcing, education, credentialing and flex pool management businesses. The company was founded on November 10, 1997 and is headquartered in Dallas, TX.

AMN Healthcare Services Inc.

AMN Healthcare is trending as strong earnings beats, a significant share repurchase program, and strategic tech partnerships signal a potential turnaround. The community is actively discussing the company's perceived undervaluation and institutional accumulation, fueling optimism for a recovery from post-pandemic normalization.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending due to its highly active community's unwavering bullish conviction and relentless promotion of its 'mind virus' meme culture, anticipating a massive viral spread and significant gains during the burgeoning Solana memecoin season.

Ankr is a Web3 decentralized infrastructure provider that helps developers, dapps, and stakers easily interact with multiple blockchains. It allows you to create DApps using API and RPC, staking on Ankr Earn, and use customized blockchain solutions for businesses.

Ankr Network

Ankr Network ($ANKR) is trending amidst sharply divided sentiment, with proponents highlighting recent developments in Web3 infrastructure, AI-focused L2 solutions, and security audits positioning it as an undervalued industry backbone with potential token burns. Conversely, a vocal part of the community expresses deep frustration, labeling it a "scam" due to prolonged price stagnation and a perceived failure to move with the broader cryptocurrency market.

Ecolab, Inc. engages in providing products and services in the field of water, hygiene, and energy. It operates through the following segments: Global Industrial, Global Institutional and Specialty, Global Healthcare and Life Sciences, Global Pest Elimination, and Corporate. The Global Industrial segment relates to water, food and beverage, paper, and downstream operating segments. The Global Institutional and Specialty segment refers to the institutional, specialty, and healthcare operating segments. The Global Healthcare and Life Sciences segment includes the healthcare and life sciences operations. The Global Pest Elimination segment provides services designed to detect, prevent and eliminate pests, such as rodents and insects, in full-service and quick-service restaurants, food and beverage processors, hotels, grocery operations, and other. The company was founded by Merritt J. Osborn in 1923 and is headquartered in St. Paul, MN.

Ecolab, Inc.

Ecolab is trending due to its strategic expansion into high-tech water and cooling solutions for the rapidly growing AI data center market, fueling community discussion around its resilient business model and potential as a long-term, innovation-driven compounder in water and hygiene.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is trending amid a highly polarized community debate, with recent financial reports sparking discussions about a potential business turnaround while its long-term viability remains contested. Bulls are focused on a significant "hidden asset" from its SumUp stake and high short interest, suggesting strategic accumulation is fueling a potential squeeze, whereas bears argue the stock is fundamentally overvalued and its price action is driven by manipulation.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack In The Box is actively discussed following news of the Del Taco sale, a move many believe will streamline operations and address substantial debt, while a high short interest and an activist investor fuel intense speculation of a potential squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Roivant Sciences (NASDAQ:ROIV) Reaches New 1-Year High - Still a Buy?

Roivant Sciences (NASDAQ:ROIV) Sets New 52-Week High - What's Next...

Roivant Sciences Q3 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) executives highlighted new Phase II results for brepocitinib in cutaneous sarcoidosis, along with a set of broader clinical and corporate milestones, during the...

Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib

(RTTNews) - Shares of Roivant Sciences Ltd. (ROIV) are climbing about 17 percent on Friday morning trading over the announcement of positive results from the Phase 2 study of brepocitinib in...

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of +9.43% and -67.32%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>In the BEACON study, patients receiving the higher 45 mg dose of brepocitinib saw substantial reductions in skin disease activity.</li><li>The trial enrolled 31 participants across U.S. clinical sites and tested two dose levels against a placebo.</li><li>Following discussions with the U.S. Food and Drug Administration, Roivant’s subsidiary,&nbsp;Priovant, plans to launch a pivotal Phase 3 study in cutaneous sarcoidosis in 2026.</li></ul>Roivant Sciences (ROIV) on Friday reported encouraging Phase 2 clinical results for its experimental oral therapy brepocitinib in adults with cutaneous sarcoidosis, while also releasing its fiscal third quarter (Q3) earnings.&nbsp;The company reported a Q3 revenue of $1.9 million and a loss per share (EPS) of $0.38. Revenue came in below the analysts’ consensus estimate of $6.14 million, while EPS surpassed the consensus, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Positive BEACON Trial Outcomes&nbsp;</h2>In the BEACON study, patients receiving the higher 45 mg dose of brepocitinib saw substantial reductions in skin disease activity compared with placebo, demonstrating statistically meaningful benefits as early as four weeks and maintained through week 16.The trial enrolled 31 participants across U.S. clinical sites and tested two dose levels against a placebo. Despite including the most treatment-resistant patients, the highest-dose group achieved rapid and sustained improvement.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/ROIV">Roivant stock</a> traded over 9% higher in Friday’s pre-market.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘normal’ message volume levels.&nbsp;<h2 class="st-heading-2">Updates On Subsidiaries’ Therapy Programs</h2>Following discussions with the U.S. Food and Drug Administration (FDA), Riovant’s subsidiary, Priovant, plans to launch a pivotal Phase 3 study in cutaneous sarcoidosis in 2026. The company has already submitted a New Drug Application for brepocitinib in dermatomyositis and expects additional Phase 3 data in non-infectious uveitis during the second half of 2026.Additionally, the company said Immunovant’s IMVT-1402 program is fully enrolled in a late-stage rheumatoid arthritis study, with results anticipated in 2026.&nbsp;Meanwhile, the firm’s subsidiary Pulmovant’s&nbsp;mosliciguat trial in pulmonary hypertension linked to interstitial lung disease is also fully enrolled.As of Dec. 31, 2025, Roivant reported approximately $4.5 billion in cash andequivalents.ROIV stock has gained over 94% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-looks-to-end-a-five-day-losing-streak-retail-believes-the-next-growth-wave-is-unfolding-now/cZbFfdXR4nD">Nvidia Looks To End A Five-Day Losing Streak – Retail Believes ‘The Next Growth Wave Is Unfolding Now’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Roivant Sciences logo is seen displayed on a smartphone screen.

Why Did Roivant Sciences Stock Gain 9% Pre-Market Today?

The company reported the Phase 2 clinical results for its experimental oral therapy brepocitinib, along with third-quarter financial data. 

Equity

The company reported the Phase 2 clinical results for its experimental oral therapy brepocitinib, along with third-quarter financial data. 


Insights into Roivant Sciences Q3 Earnings

Roivant Sciences (ROIV) to Release Quarterly Earnings on Friday

Roivant Sciences (NASDAQ:ROIV) will be releasing its Q3 2026 earnings before the market opens on Friday, February 6. (View Earnings Report at...

Parkside Financial Bank & Trust Has $10.57 Million Holdings in Roivant Sciences Ltd. $ROIV

Parkside Financial Bank & Trust trimmed its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 46.7% in the third quarter, according to its most recent Form 13F filing with the Securities...

Campbell & CO Investment Adviser LLC Sells 68,705 Shares of Roivant Sciences Ltd. $ROIV

Campbell & CO Investment Adviser LLC trimmed its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 65.8% during the third quarter, according to its most recent disclosure with the...

Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the company's stock in a transaction that occurred on Monday, January 12th. The stock was sold at an...

$ROIV Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.38
• Reported revenue of $2M

Stocktwits

Roivant Sciences Ltd

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.38
• Reported revenue of $2M

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

What will be the S&P 500’s next 5% move?

Current Price	$25.70
Prev Close	$21.14
Open	$24.48
Dividend Yield	0.00%
50-Day Moving Average	$21.97
Beta	0.85
Avg. Volume	5.73M
PE Ratio	-22.10

52-Week High	$25.95
52-Week Low	$8.73
Market Capitalization	$17.96B
EPS (Annual)	-$0.2371
Price to Book	4.29
Revenue Per Employee	$38,737.33
Enterprise Value/EBITDA	N/A

ROIV
Roivant Sciences Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ROIV News

ROIVRoivant Sciences Ltd